Exploring the Feasibility of fusidic acid phonophoresis as complementary therapy on bacterial analysis in chronic rhinosinusitis a randomised controlled trial - nil

开始日期2024-02-14

申办/合作机构-

NCT05398679 / Not yet recruiting临床4期IIT

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

Non-inferiority trial to determine whether partial oral treatment is non-inferior to OPAT(Outpatient parenteral therapy) in patients diagnosed with infective endocarditis

开始日期2022-06-01

申办/合作机构-

NCT05074147 / Not yet recruiting临床3期

Three Weeks Versus Six Weeks Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis : a Multicenter, Randomized, Open-label and Controlled Study

The aim of this clinical study is to compare the efficacy and tolerance of 3 versus 6 weeks of antibiotherapy in patients with diabetic foot osteomyelitis treated medically.

开始日期2022-05-01

申办/合作机构

Centre Hospitalier de Tourcoing

100 项与夫西地酸相关的临床结果

登录后查看更多信息

100 项与夫西地酸相关的转化医学

登录后查看更多信息

100 项与夫西地酸相关的专利（医药）

登录后查看更多信息

2,099

项与夫西地酸相关的文献（医药）

2024-02-23·ACS applied bio materials

A Nanocomposite Dynamic Covalent Cross-Linked Hydrogel Loaded with Fusidic Acid for Treating Antibiotic-Resistant Infected Wounds.

Article

作者: Samaneh Toufanian ; Jody Mohammed ; Erica Winterhelt ; Andrew Lofts ; Ridhdhi Dave ; Brian K Coombes ; Todd Hoare

Methicillin-resistant Staphylococcus aureus (MRSA) is associated with high levels of morbidity and is considered a difficult-to-treat infection, often requiring nonstandard treatment regimens and antibiotics. Since over 40% of the emerging antibiotic compounds have insufficient solubility that limits their bioavailability and thus efficacy through oral or intravenous administration, it is crucial that alternative drug delivery products be developed for wound care applications. Existing effective treatments for soft tissue MRSA infections, such as fusidic acid (FA), which is typically administered orally, could also benefit from alternative routes of administration to improve local efficacy and bioavailability while reducing the required therapeutic dose. Herein, we report an antimicrobial poly(oligoethylene glycol methacrylate) (POEGMA)-based composite hydrogel loaded with fusidic acid-encapsulating self-assembled polylactic acid-b-poly(oligo(ethylene glycol) methyl ether methacrylate) (PLA-POEGMA) nanoparticles for the treatment of MRSA-infected skin wounds. The inclusion of the self-assembled nanoparticles (380 nm diameter when loaded with fusidic acid) does not alter the favorable mechanical properties and stability of the hydrogel in the context of its use as a wound dressing, while fusidic acid (FA) can be released from the hydrogel over ∼10 h via a diffusion-controlled mechanism. The antimicrobial studies demonstrate a clear zone of inhibition in vitro and a 1-2 order of magnitude inhibition of bacterial growth in vivo in an MRSA-infected full-thickness excisional murine wound model even at very low antibiotic doses. Our approach thus can both circumvent challenges in the local delivery of hydrophobic antimicrobial compounds and directly deliver antimicrobials into the wound to effectively combat methicillin-resistant infections using a fraction of the drug dose required using other clinically relevant strategies.

2024-02-11·Bioengineering (Basel, Switzerland)

Reversing the Natural Drug Resistance of Gram-Negative Bacteria to Fusidic Acid via Forming Drug-Phospholipid Complex.

Article

作者: Jianhong Liu ; Xuyang Lai ; Yuanhong Li ; Zhuohang Yu ; Xuan Wang ; Chaoliang Zhang ; Qiang Peng

Drug resistance substantially compromises antibiotic therapy and poses a serious threat to public health. Fusidic acid (FA) is commonly used to treat staphylococcal infections, such as pneumonia, osteomyelitis and skin infections. However, Gram-negative bacteria have natural resistance to FA, which is almost restrained in cell membranes due to the strong interactions between FA and phospholipids. Herein, we aim to utilize the strong FA-phospholipid interaction to pre-form a complex of FA with the exogenous phospholipid. The FA, in the form of an FA-phospholipid complex (FA-PC), no longer interacts with the endogenous membrane phospholipids and thus can be delivered into bacteria cells successfully. We found that the water solubility of FA (5 µg/mL) was improved to 133 µg/mL by forming the FA-PC (molar ratio 1:1). Furthermore, upon incubation for 6 h, the FA-PC (20 µg/mL) caused a 99.9% viability loss of E. coli and 99.1% loss of P. aeruginosa, while free FA did not work. The morphology of the elongated bacteria cells after treatment with the FA-PC was demonstrated by SEM. The successful intracellular delivery was shown by confocal laser scanning microscopy in the form of coumarin 6-PC (C6-PC), where C6 served as a fluorescent probe. Interestingly, the antibacterial effect of the FA-PC was significantly compromised by adding extra phospholipid in the medium, indicating that there may be a phospholipid-based transmembrane transport mechanism underlying the intracellular delivery of the FA-PC. This is the first report regarding FA-PC formation and its successful reversing of Gram-negative bacteria resistance to FA, and it provides a platform to reverse transmembrane delivery-related drug resistance. The ready availability of phospholipid and the simple preparation allow it to have great potential for clinical use.

2024-02-10·BMC microbiology

The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model.

Article

作者: Salwa E Gomaa ; Hisham A Abbas ; Fatma A Mohamed ; Mohamed A M Ali ; Tarek M Ibrahim ; Alyaa S Abdel Halim ; Mashael A Alghamdi ; Basem Mansour ; Anis Ahmad Chaudhary ; Amr Elkelish ; Fehmi Boufahja ; Wael A H Hegazy ; Fatma Al-Zahraa A Yehia

BACKGROUND:

Candida albicans is the most common fungus that causes vaginal candidiasis in immunocompetent women and catastrophic infections in immunocompromised patients. The treatment of such infections is hindered due to the increasing emergence of resistance to azoles in C. albicans. New treatment approaches are needed to combat candidiasis especially in the dwindled supply of new effective and safe antifungals. The resistance to azoles is mainly attributed to export of azoles outside the cells by means of the efflux pump that confers cross resistance to all azoles including fluconazole (FLC).

OBJECTIVES:

This study aimed to investigate the possible efflux pump inhibiting activity of fusidic acid (FA) in C. albicans resistant isolates and the potential use of Fusidic acid in combination with fluconazole to potentiate the antifungal activity of fluconazole to restore its activity in the resistant C. albicans isolates.

METHODS:

The resistance of C. albicans isolates was assessed by determination of minimum inhibitory concentration. The effect of Fusidic acid at sub-inhibitory concentration on efflux activity was assayed by rhodamine 6G efflux assay and intracellular accumulation. Mice model studies were conducted to evaluate the anti-efflux activity of Fusidic acid and its synergistic effects in combination with fluconazole. Impact of Fusidic acid on ergosterol biosynthesis was quantified. The synergy of fluconazole when combined with Fusidic acid was investigated by determination of minimum inhibitory concentration. The cytotoxicity of Fusidic acid was tested against erythrocytes. The effect of Fusidic acid on efflux pumps was tested at the molecular level by real-time PCR and in silico study. In vivo vulvovaginitis mice model was used to confirm the activity of the combination in treating vulvovaginal candidiasis.

RESULTS:

Fusidic acid showed efflux inhibiting activity as it increased the accumulation of rhodamine 6G, a substrate for ABC-efflux transporter, and decreased its efflux in C. albicans cells. The antifungal activity of fluconazole was synergized when combined with Fusidic acid. Fusidic acid exerted only minimal cytotoxicity on human erythrocytes indicating its safety. The FA efflux inhibitory activity could be owed to its ability to interfere with efflux protein transporters as revealed by docking studies and downregulation of the efflux-encoding genes of both ABC transporters and MFS superfamily. Moreover, in vivo mice model showed that using fluconazole-fusidic acid combination by vaginal route enhanced fluconazole antifungal activity as shown by lowered fungal burden and a negligible histopathological change in vaginal tissue.

CONCLUSION:

The current findings highlight FA's potential as a potential adjuvant to FLC in the treatment of vulvovaginal candidiasis.

项与夫西地酸相关的新闻（医药）

2024-03-29

·药通社

高迈药业：专注于外用药的药学研发（乳膏，软膏，凝胶，外用溶液，贴剂） | 邀您共赴广州MAH B证企业论坛

2024.4.24 • 中国广州2024MAH B证沙龙展位号：A11号展位分布▼关于高迈药业苏州高迈药业有限公司成立于2018年，即将搬迁至生物医药产业园四期，研发场地面积11000平方米；专注于外用药的药学研发（乳膏，软膏，凝胶，外用溶液，贴剂）；团队由日本的技术、生产人员领衔，国内知名高校教授为顾问团队；核心管理人员均具有多年的研发管理经验；目前已有1个外用药项目获批，2个创新药的临床1期批件，已申报3个产品。公司致力于“高端仿制”“改良型新药”“自主创新药”三步走战略，打造专业外用药“第一股”。项目清单序号项目名称适应症分类1利丙双卡因乳膏局麻2盐酸利多卡因凝胶局麻3盐酸丁卡因凝胶局麻4利多卡因丁卡因乳膏局麻5利多卡因凝胶贴膏局麻6利多卡因喷雾剂局麻7阿达帕林凝胶痤疮8过氧苯甲酰凝胶痤疮9阿达帕林过氧苯甲酰凝胶痤疮10克拉司酮乳膏痤疮11壬二酸凝胶痤疮12夫西地酸乳膏抗感染13莫匹罗星软膏抗感染14伊维菌素乳膏抗感染15复方多粘菌素B软膏抗感染16阿昔洛韦氢化可的松乳膏抗感染17双唑泰乳膏抗感染18盐酸氨酮戊酸外用散抗感染19双氯芬酸二乙胺乳胶剂镇痛20氟比洛芬凝胶贴膏镇痛21双氯芬酸依泊胺贴镇痛22酮洛芬凝胶镇痛23洛索洛芬钠凝胶贴膏镇痛24洛索洛芬钠贴剂镇痛25双氯芬酸钠贴剂镇痛26布洛芬乳膏镇痛27盐酸阿莫罗芬乳膏抗真菌28硝酸咪康唑乳膏抗真菌29盐酸特比萘芬喷雾剂抗真菌30盐酸特比萘芬乳膏抗真菌31盐酸特比萘芬涂膜剂抗真菌32联苯苄唑溶液抗真菌33卢立康唑乳膏抗真菌34曲安奈德益康唑乳膏抗真菌35盐酸阿莫罗芬搽剂抗真菌36艾氟康唑外用溶液抗真菌37硝酸益康唑气雾剂抗真菌38西甲硅油乳剂胀气39利多卡因丙胺卡因气雾剂早泄40卡泊三醇软膏银屑病41非那雄胺喷雾剂脱发42氢醌乳膏黄褐斑43维氟醌乳膏(氟轻松氢醌维A酸乳膏)黄褐斑44尿素乳膏皲裂45妥洛特罗贴剂气管炎46克立硼罗软膏皮炎47糠酸莫米松乳膏皮炎48丙酸氟替卡松乳膏皮炎49磷酸芦可替尼乳膏皮炎50复方倍他米松樟脑乳膏皮炎51曲咪新乳膏皮炎52多磺酸粘多糖乳膏静脉曲张53黄体酮阴道缓释凝胶激素补充54雌二醇凝胶激素补充55雌二醇贴片激素补充56美沙拉嗪栓肠炎57奥昔布宁透皮贴剂膀胱过动58氟维司群乳膏乳腺癌59克霉唑阴道乳膏阴道炎60硝呋太尔制霉菌素阴道软膏阴道炎设备及资质01透皮仪02粘度计联系我们联系人：陈先生 18006207168欢迎扫码报名广州 MAH 沙龙 9:00-9:40132号文新政实施后，如何办B证？药监专家9:40-10:10批文&项目合作路演限时免费报名中10:10-10:40茶歇10:40-11:20B证企业迎接检查注意点及缺陷案例药监专家11:20-12:00MAH制度下集采和医保政策解析许金灿，药闻康策创始人兼总经理12:00-14:00茶歇14:00-14:30药品上市许可持有人变更审批及案例分享药监专家14:30-15:00从欧美MAH监管体系看中国药品制度创新之路杜新，前FDA CMC审评专家，埃格林医药总经理15:00-15:30批文&项目合作路演限时免费报名中15:30-15:50茶歇15:50-16:20B证企业关键人员能力素养要求谢海燕，丽珠集团党委委员、质量管理总部总经理、广东省药学会质量受权人专委会主任委员16:20-16:50新形势下持有人产品立项考量赵忠卫，深圳奥祺生物医药有限公司总经理*议程更新中，以现场为准*报名参会限时免费，食宿自理（联系参会人员参与免费领餐券活动）扫描下方二维码！免费！免费！免费报名

申请上市临床1期

2024-03-11

·信狐药迅

葆元生物1类新药己二酸他雷替尼提交上市申请| 新受理（3.4-3.10）

本周药品注册受理数据，分门别类呈现，一目了然。(3.4-3.10）新药上市申请药品名称企业注册分类受理号己二酸他雷替尼胶囊葆元生物医药科技(杭州)有限公司1CXHS2400020注射用隆培促生长素Ascendis Pharma Endocrinology Division A/S3.1JXSS2400025注射用隆培促生长素Ascendis Pharma Endocrinology Division A/S3.1JXSS2400024注射用隆培促生长素Ascendis Pharma Endocrinology Division A/S3.1JXSS2400023注射用隆培促生长素Ascendis Pharma Endocrinology Division A/S3.1JXSS2400022注射用隆培促生长素Ascendis Pharma Endocrinology Division A/S3.1JXSS2400021注射用隆培促生长素Ascendis Pharma Endocrinology Division A/S3.1JXSS2400020注射用隆培促生长素Ascendis Pharma Endocrinology Division A/S3.1JXSS2400019注射用隆培促生长素Ascendis Pharma Endocrinology Division A/S3.1JXSS2400018注射用隆培促生长素Ascendis Pharma Endocrinology Division A/S3.1JXSS2400017新药临床申请药品名称企业注册分类受理号EB160片中山优理生物医药有限公司1CXHL2400263EB160片中山优理生物医药有限公司1CXHL2400262EB160片中山优理生物医药有限公司1CXHL2400261HRS9531片福建盛迪医药有限公司1CXHL2400256HRS9531片福建盛迪医药有限公司1CXHL2400255HRS9531片福建盛迪医药有限公司1CXHL2400254HRS9531片福建盛迪医药有限公司1CXHL2400253HRS9531片福建盛迪医药有限公司1CXHL2400252HRS9531片福建盛迪医药有限公司1CXHL2400251HRS9531片福建盛迪医药有限公司1CXHL2400250HRS9531片福建盛迪医药有限公司1CXHL2400249SPH7450片上海医药集团股份有限公司1CXHL2400260SPH7450片上海医药集团股份有限公司1CXHL2400259SPH7450片上海医药集团股份有限公司1CXHL2400258SPH7450片上海医药集团股份有限公司1CXHL2400257DGPR1008注射液新斗生物科技(苏州)有限公司1CXHL2400243BGB-24714胶囊百济神州(苏州)生物科技有限公司1CXHL2400239注射用LYSC98浙江医药股份有限公司新昌制药厂1CXHL2400236BGB-24714胶囊百济神州(苏州)生物科技有限公司1CXHL2400238BGB-24714胶囊百济神州(苏州)生物科技有限公司1CXHL2400237BTP0209江苏诺和必拓新药研发有限公司2.2CXHL2400242BTP0209江苏诺和必拓新药研发有限公司2.2CXHL2400241BTP0209江苏诺和必拓新药研发有限公司2.2CXHL2400240醋酸地非法林注射液齐鲁制药(海南)有限公司3CYHL2400051注射用MK-2870默沙东研发(中国)有限公司1CXSL2400175SYS6002石药集团巨石生物制药有限公司1CXSL2400174注射用SKB501四川科伦博泰生物医药股份有限公司1CXSL2400172仿制药申请药品名称企业注册分类受理号复方氨基酸（16）双肽（1）注射液内蒙古白医制药股份有限公司3CYHS2400802复方氨基酸（16）双肽（1）注射液内蒙古白医制药股份有限公司3CYHS2400801腺苷钴胺胶囊湖南千金湘江药业股份有限公司3CYHS2400793盐酸溴己新注射液安徽新世纪药业有限公司3CYHS2400788盐酸艾司洛尔注射液河北龙海药业有限公司3CYHS2400786利多卡因丁卡因乳膏江苏盈科生物制药有限公司3CYHL2400056布立西坦片四川科伦药业股份有限公司3CYHL2400055布立西坦片四川科伦药业股份有限公司3CYHL2400054布立西坦片四川科伦药业股份有限公司3CYHL2400053盐酸左沙丁胺醇雾化吸入溶液福建天泉药业股份有限公司3CYHS2400780氯化钾颗粒浙江赛默制药有限公司3CYHS2400778奥扎格雷钠注射液赤峰经方医药技术开发有限责任公司3CYHS2400776奥扎格雷钠注射液赤峰经方医药技术开发有限责任公司3CYHS2400775帕立骨化醇软胶囊成都盛迪医药有限公司3CYHS2400772帕立骨化醇软胶囊成都盛迪医药有限公司3CYHS2400770酒石酸阿福特罗雾化吸入用溶液海南斯达制药有限公司3CYHL2400052醋酸地非法林注射液齐鲁制药(海南)有限公司3CYHL2400051帕拉米韦注射液浙江诚意药业股份有限公司3CYHS2400760琥珀酸地文拉法辛缓释片扬子江药业集团有限公司3CYHS2400759琥珀酸地文拉法辛缓释片扬子江药业集团有限公司3CYHS2400758盐酸肾上腺素注射液马鞍山丰原制药有限公司3CYHS2400756福多司坦口服溶液成都欣捷高新技术开发股份有限公司3CYHS2400755福多司坦口服溶液成都欣捷高新技术开发股份有限公司3CYHS2400754盐酸甲氧氯普胺注射液海南天盛保和生物科技有限公司3CYHS2400753甲硫酸新斯的明注射液南京海辰药业股份有限公司3CYHS2400752甲硫酸新斯的明注射液南京海辰药业股份有限公司3CYHS2400751甲硫酸新斯的明注射液南京海辰药业股份有限公司3CYHS2400750复方氨基酸注射液（18AA-Ⅸ）广东赛烽医药科技有限公司4CYHS2400805比拉斯汀片石家庄四药有限公司4CYHS2400804夫西地酸乳膏浙江众延医药科技有限公司4CYHS2400803吸入用乙酰半胱氨酸溶液朗天药业(湖北)有限公司4CYHS2400800他达拉非片贵州圣济堂制药有限公司4CYHS2400799他达拉非片贵州圣济堂制药有限公司4CYHS2400798甲钴胺片湖南状元制药有限公司4CYHS2400797洛索洛芬钠凝胶膏宁波美舒医药科技有限公司4CYHS2400796氢溴酸伏硫西汀片合肥创新医药技术有限公司4CYHS2400795氢溴酸伏硫西汀片合肥创新医药技术有限公司4CYHS2400794沙库巴曲缬沙坦钠片湖南千金协力药业有限公司4CYHS2400792利丙双卡因乳膏宁波美舒医药科技有限公司4CYHS2400791磷酸西格列汀片湖南威特制药股份有限公司4CYHS2400790地夸磷索钠滴眼液重庆苯立方医药科技有限公司4CYHS2400789氟哌噻吨美利曲辛片成都倍特药业股份有限公司4CYHS2400787蒙脱石混悬液国药控股星鲨制药(厦门)有限公司4CYHS2400785氟比洛芬凝胶贴膏浙江百代医药科技有限公司4CYHL2400057比索洛尔氨氯地平片浙江花园药业有限公司4CYHS2400784富马酸伏诺拉生片海南皇隆制药股份有限公司4CYHS2400783富马酸伏诺拉生片海南皇隆制药股份有限公司4CYHS2400782注射用头孢米诺钠山东宜和生物医药科技有限公司4CYHS2400781瑞巴派特片北京天衡药物研究院南阳天衡制药厂4CYHS2400779尼可地尔片北京四环科宝制药股份有限公司4CYHS2400774盐酸贝尼地平片北京福元医药股份有限公司4CYHS2400773硫酸氨基葡萄糖胶囊成都恒瑞制药有限公司4CYHS2400771乳果糖口服溶液成都倍特得诺药业有限公司4CYHS2400769乳果糖口服溶液成都倍特得诺药业有限公司4CYHS2400768艾地骨化醇软胶囊山东新时代药业有限公司4CYHS2400767硫酸羟氯喹片湖北午时医药研究院有限公司4CYHS2400766硫酸氨基葡萄糖胶囊四川成都同道堂制药有限责任公司4CYHS2400777精氨酸布洛芬颗粒中山万汉制药有限公司4CYHS2400765精氨酸布洛芬颗粒中山万汉制药有限公司4CYHS2400764培哚普利氨氯地平片（Ⅲ）杭州康恩贝制药有限公司4CYHS2400763注射用替考拉宁泊诺(天津)创新医药研究有限公司4CYHS2400762妥布霉素滴眼液浙江赛默制药有限公司4CYHS2400761聚乙烯醇滴眼液四川海梦智森生物制药有限公司4CYHS2400757维格列汀片新天地药业股份有限公司4CYHS2400749进口申请药品名称企业注册分类受理号Vorasidenib片Institut de Recherches Internationales Servier1JXHL2400061Vorasidenib片Institut de Recherches Internationales Servier1JXHL2400060Lu AF28996 胶囊H. Lundbeck A/S1JXHL2400056Lu AF28996 胶囊H. Lundbeck A/S1JXHL2400055Lu AF28996 胶囊H. Lundbeck A/S1JXHL2400054Lu AF28996 胶囊H. Lundbeck A/S1JXHL2400053ARV-471(PF-07850327)片Pfizer Inc.1JXHL2400052呼吸道合胞病毒减毒活疫苗Sanofi Pasteur Inc.1.1JXSL2400058Vixarelimab 注射液Genentech, Inc.1JXSL2400056中药相关申请药品名称企业注册分类受理号母苏颗粒瑞阳制药股份有限公司1.1CXZL2400013不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市临床结果

2024-02-28

·米内网

【市场】2亿抗血栓药，福元医药拿下

精彩内容2月27日，福元医药公告称，公司以仿制3类报产的西洛他唑片获批上市并视同过评，为国内第2家过评。西洛他唑片属于抗血栓形成药，2022年在中国公立医疗机构终端销售额超过2亿元。西洛他唑是一种抗血小板抑制剂，可以选择性抑制磷酸二酯酶Ⅲ活性，使细胞内cAMP水平升高，从而发挥抗血小板聚集和扩张血管等作用；用于改善由于慢性动脉闭塞症引起的溃疡、肢痛、冷感及间歇性跛行等缺血性症状，以及预防脑梗死复发（不包括心源性脑梗死）。中国公立医疗机构终端西洛他唑片销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局米内网数据显示，2022年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端西洛他唑片销售额超过2亿元，其中大冢制药占据80.8%的市场份额。目前国内已有22家药企获得了西洛他唑片的生产批文，其中江苏吴中医药的西洛他唑片于2024年1月4日率先通过仿制药一致性评价，此次福元医药的的西洛他唑片获批上市并视同过评，为国内第2家过评。2023年至今福元医药获批产品来源：米内网中国申报进度（MED）数据库2023年至今，福元医药已有7个品种获批上市并视同过评，包括西洛他唑片、夫西地酸乳膏、氟伐他汀钠缓释片、磷酸西格列汀片、替米沙坦氢氯噻嗪片、沙格列汀二甲双胍缓释、他克莫司软膏。资料来源：米内网数据库、公司公告注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准一致性评价

100 项与夫西地酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04281	夫西地酸	D09AA02 S01AA13 J01XC01 D06AX01	DB02703

研发状态

适应症	最高研发状态	国家/地区	公司
继发感染	批准上市	日本更多	Alfresa Pharma Corp. 更多
细菌感染	批准上市	中国更多	LEO Pharmaceutical Products OOO 更多
细菌性结膜炎	批准上市	英国更多	Amdipharm Uk Ltd. 更多
细菌性皮肤疾病	无进展	美国更多	Arrevus, Inc.初创企业更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2004	N/A	细菌性眼感染	532	Gatifloxacin	衊鏇鏇餘鏇襯廠艱醖夢(鏇蓋築艱醖積襯觸蓋選) = 觸顧艱鬱齋選蓋鑰網鑰鑰壓範壓鬱壓襯蓋鬱獵 (艱製願顧襯簾壓製範願 )	-	2004-05-01
				Ciprofloxacin	衊鏇鏇餘鏇襯廠艱醖夢(鏇蓋築艱醖積襯觸蓋選) = 網築構網顧膚艱窪夢網鑰壓範壓鬱壓襯蓋鬱獵 (艱製願顧襯簾壓製範願 )
NCT02570490 (GlobeNewswire) 人工标引	临床3期	皮肤和皮肤结构感染	716	Fusidic acid	(鹹遞築遞窪選壓窪構築) = 鏇製簾壓鏇鬱鏇簾鹽網鏇醖網齋鏇淵淵廠鏇觸 (積獵積壓鏇糧願蓋憲選 ) 更多	非劣	2017-02-24
				linezolid	(鹹遞築遞窪選壓窪構築) = 憲壓夢積壓顧顧窪鏇鹹鏇醖網齋鏇淵淵廠鏇觸 (積獵積壓鏇糧願蓋憲選 ) 更多
EADV2022	N/A	化脓性汗腺炎	49	Fusidic acid	獵鹽遞襯艱廠憲窪鬱獵(顧觸壓願蓋簾鹽鏇構醖) = Adverse reactions occurred in 27.3% (15 TC), mostly within the first 4 weeks of treatment (63.6%). The majority were gastrointestinal symptoms (21.8%, 12 TC), which led to discontinuation of treatment in 12.7%. 網獵蓋襯襯窪遞襯鑰蓋 (遞糧齋鹽憲醖繭淵鬱鹽 )	-	2022-09-07